IQVIA and Medera Forge Strategic Collaboration to Accelerate Cardiac Gene Therapy and Human-Based Drug Discovery
核心洞察
IQVIA and Medera announced a strategic collaboration on August 4, 2026, to accelerate cardiac gene therapy development and human-based drug discovery platforms.
The partnership leverages IQVIA's global clinical trial infrastructure alongside Medera's Sardocor (搜索) gene therapy programs and Novoheart (搜索) mini-Heart platform.
Sardocor (搜索)'s FDA-cleared, first-in-human AAV-based gene therapy (搜索) programs will benefit from IQVIA's regulatory expertise and patient recruitment support.
IQVIA, a leading global provider of clinical research services and healthcare intelligence, and Medera Inc. (搜索), a clinical-stage biopharmaceutical company focused on next-generation cardiovascular therapeutics, have entered into a strategic collaboration aimed at accelerating the development of cardiac gene therapies and advancing human-based drug discovery platforms. The partnership, announced on August 4, 2026, from Research Triangle Park, N.C. and Boston, brings together complementary capabilities designed to streamline the path from preclinical innovation to clinical validation and regulatory approval.
The collaboration unites IQVIA's expansive global clinical trial and commercialization infrastructure with two of Medera's pioneering platforms: Sardocor (搜索), the company's clinical development arm advancing a pipeline of disease-modifying gene therapies for difficult-to-treat cardiovascular diseases, and Novoheart (搜索), a leader in engineered human-based cardiac tissue for disease modeling and drug screening.
Sardocor (搜索): Advancing AAV-Based Cardiac Gene Therapies
Under the agreement, Sardocor (搜索) will leverage IQVIA's regulatory and trial execution expertise to advance its FDA-cleared, first-in-human AAV-based gene therapy (搜索) programs. IQVIA will provide support across multiple critical functions, including patient recruitment, data quality management, and regulatory filings. The collaboration also encompasses applications for expedited FDA designations, signaling an intent to bring these therapies to patients through accelerated regulatory pathways.
Sardocor (搜索)'s pipeline targets a range of cardiovascular conditions, including heart failure with preserved ejection fraction (搜索) (HFpEF), heart failure with reduced ejection fraction (搜索) (HFrEF), and Duchenne muscular dystrophy-associated cardiomyopathy (搜索) (DMD-CM).
Novoheart (搜索): Human-Based Drug Discovery Under FDA Modernization Act 2.0
Novoheart (搜索)'s mini-Heart platform represents a significant advancement in human-relevant drug discovery. The platform has already proven instrumental in securing Investigational New Drug (IND) and Fast Track designations from the FDA, offering a predictive, human-based alternative to traditional animal testing. The platform is currently expanding into multiple organ systems to support broader drug discovery and safety testing applications, operating within the framework of the FDA Modernization Act 2.0, which encourages the use of alternative methods to animal testing in drug development.
"By combining IQVIA's global expertise with Medera's mini-Heart platform and gene therapy programs, we can bring safer, more effective therapies to patients faster," said Ronald Li, Co-Founder, Chairman and CEO of Medera. "This collaboration expands our reach, while reinforcing the scientific and regulatory momentum around human-based drug discovery and cardiac gene therapy innovation."
The collaboration positions both companies to address significant unmet needs in cardiovascular medicine, where difficult-to-treat and currently incurable diseases such as HFpEF, HFrEF, and DMD-CM continue to represent areas of high clinical demand. Medera's broader pipeline extends beyond gene therapy to include cell therapy and small molecule candidates, suggesting potential for further expansion of the collaboration's scope over time.